Statements (14)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:approves |
gptkb:U._S._Food_and_Drug_Administration
July 2020 |
| gptkbp:clinical_trial |
Phase 2
|
| gptkbp:developed_by |
gptkb:Incyte_Corporation
|
| https://www.w3.org/2000/01/rdf-schema#label |
Monjuvi
|
| gptkbp:ingredients |
tafasitamab
|
| gptkbp:marketed_as |
gptkb:Monjuvi
|
| gptkbp:mechanism_of_action |
CD19-targeting monoclonal antibody
|
| gptkbp:route_of_administration |
intravenous infusion
|
| gptkbp:used_for |
treatment of diffuse large B-cell lymphoma
|
| gptkbp:bfsParent |
gptkb:Incyte_Biosciences
gptkb:Tafasitamab |
| gptkbp:bfsLayer |
6
|